PE20000021A1 - Eteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p - Google Patents
Eteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia pInfo
- Publication number
- PE20000021A1 PE20000021A1 PE1998001112A PE00111298A PE20000021A1 PE 20000021 A1 PE20000021 A1 PE 20000021A1 PE 1998001112 A PE1998001112 A PE 1998001112A PE 00111298 A PE00111298 A PE 00111298A PE 20000021 A1 PE20000021 A1 PE 20000021A1
- Authority
- PE
- Peru
- Prior art keywords
- disorders
- alkyl
- haloalkyl
- compound
- emergency
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES ALQUILO C1-C6; R2 ES H, ALQUILO C1-C6, HALOALQUILO C1-C6 o FENILO; R3 ES H o HALOGENO; R4 Y R5 SON H, ALQUILO C1-C6 o HALOALQUILO C1-C6; n ES 1-3. SON COMPUESTOS PREFERIDOS (2S,3S)-3-[(1R)-(6-METOXI-1-METIL-1-TRIFLUOROMETILISOCROMAN-7-IL]METILAMINO-2-FENILPIPERIDINA; (2S,3S)-3-[(3R)-(6-METOXI)-3-METIL-3-TRIFLUOROMETIL-1,3-DIHIDROBENZOFURAN-5-IL)METILAMINO-2-FENILPIPERIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN COMPUESTO DE FORMULA III, DONDE W ES H o Q(O=)C-; Q ES H, ALQUILO C1-C6, HALOALQUILO C1-C6. EL COMPUESTO I ES UN ANTAGONISTA DE LA SUSTANCIA P (PEPTIDO DE LA TAQUICININA) Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, TRASTORNOS ALERGICOS, ANGIOGENESIS, TRASTORNOS GASTROINTESTINALES, TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, ENFERMEDADES INFLAMATORIAS, EMESIS, INCONTINENCIA URINARIA, DOLOR, MIGRANA, TRASTORNOS DE ANSIEDAD SEVERA, TRASTORNOS DE ESTRES, QUEMADURAS SOLARES, TRASTORNOS PROVOCADOS POR HELICOBACTER PILORI, DISFUNCION SEXUAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB9701466 | 1997-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000021A1 true PE20000021A1 (es) | 2000-02-25 |
Family
ID=11004634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998001112A PE20000021A1 (es) | 1997-11-19 | 1998-11-16 | Eteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US20030208079A1 (es) |
| EP (1) | EP1032571B1 (es) |
| JP (2) | JP3394239B2 (es) |
| KR (1) | KR100366902B1 (es) |
| CN (1) | CN1173974C (es) |
| AP (1) | AP909A (es) |
| AR (1) | AR016422A1 (es) |
| AT (1) | ATE219078T1 (es) |
| AU (1) | AU734218B2 (es) |
| BG (1) | BG63969B1 (es) |
| CA (1) | CA2310627C (es) |
| CO (1) | CO4771153A1 (es) |
| CZ (1) | CZ297315B6 (es) |
| DE (1) | DE69806045T2 (es) |
| DK (1) | DK1032571T3 (es) |
| DZ (1) | DZ2655A1 (es) |
| EA (1) | EA002621B1 (es) |
| ES (1) | ES2177058T3 (es) |
| HK (1) | HK1033313A1 (es) |
| HR (1) | HRP20000313B1 (es) |
| HU (1) | HUP0101112A3 (es) |
| ID (1) | ID24240A (es) |
| IL (1) | IL135631A0 (es) |
| IS (1) | IS2202B (es) |
| MA (1) | MA26567A1 (es) |
| MY (1) | MY120558A (es) |
| NO (2) | NO20002544L (es) |
| NZ (1) | NZ503912A (es) |
| OA (1) | OA11380A (es) |
| PA (1) | PA8463001A1 (es) |
| PE (1) | PE20000021A1 (es) |
| PL (1) | PL193484B1 (es) |
| PT (1) | PT1032571E (es) |
| RS (1) | RS49792B (es) |
| SK (1) | SK283460B6 (es) |
| TN (1) | TNSN98210A1 (es) |
| TR (1) | TR200001463T2 (es) |
| TW (1) | TW426667B (es) |
| UA (1) | UA59417C2 (es) |
| WO (1) | WO1999025714A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9812662D0 (en) * | 1998-06-11 | 1998-08-12 | Merck Sharp & Dohme | Therapeutic use |
| GB9812617D0 (en) * | 1998-06-11 | 1998-08-12 | Merck Sharp & Dohme | Therapeutic use |
| EA200101050A1 (ru) * | 1999-05-06 | 2002-04-25 | Пфайзер Продактс Инк. | Замещенные бензолактамные соединения |
| RS49964B (sr) | 1999-05-17 | 2008-09-29 | Pfizer Products Inc., | Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli |
| ATE234832T1 (de) * | 1999-05-21 | 2003-04-15 | Pfizer Prod Inc | 1-trifluorotmethyl-4-hydroxy-7-piperidinyl- aminomethylchroman-derivate |
| AU7557000A (en) * | 1999-10-07 | 2001-05-10 | Hisamitsu Pharmaceutical Co. Inc. | Piperidine derivatives |
| PT1095939E (pt) * | 1999-10-18 | 2004-04-30 | Pfizer Prod Inc | Processo para a preparacao de eteres ciclicos de compostos com piperidinilaminometilo |
| JP2001172178A (ja) * | 1999-10-25 | 2001-06-26 | Pfizer Prod Inc | 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン |
| IL142810A0 (en) * | 2000-05-03 | 2002-03-10 | Pfizer Prod Inc | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles |
| US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
| EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| DK1288208T3 (da) | 2001-08-30 | 2006-10-16 | Pfizer Prod Inc | Fremgangsmåde til fremstilling af 2-(4-alkyl-1-piperazinyl)-benzaldehyd- og -benzylidenforbindelser ved nucleofil aromatisk substituering af 2-flourbenzaldehyd med 4-alkyl-1-peperazin i vand som oplösningsmiddel |
| US20040001895A1 (en) * | 2002-06-17 | 2004-01-01 | Pfizer Inc. | Combination treatment for depression and anxiety |
| AU2003262773A1 (en) * | 2002-08-27 | 2004-03-19 | David T. Harris | Amelioration of effects of cigarette smoke |
| US6911544B2 (en) * | 2002-10-23 | 2005-06-28 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine |
| US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
| DE102008000891A1 (de) | 2008-03-31 | 2009-10-01 | Robert Bosch Gmbh | Schutzsystem für Werkzeugmaschinen |
| NO2729147T3 (es) | 2011-07-04 | 2018-02-03 | ||
| CN111918647A (zh) | 2018-02-26 | 2020-11-10 | 圣拉斐尔医院有限公司 | 用于治疗眼痛的nk-1拮抗剂 |
| US20230134843A1 (en) | 2020-03-11 | 2023-05-04 | Ospedale San Raffaele S.R.L. | Treatment of stem cell deficiency |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9317987D0 (en) * | 1993-08-26 | 1993-10-13 | Glaxo Group Ltd | Chemical compounds |
| US5886011A (en) * | 1995-03-27 | 1999-03-23 | Hisamitsu Pharmaceutical Co., Inc. | Piperidine derivatives as substance P antagonists |
| TW475930B (en) * | 1995-04-24 | 2002-02-11 | Novartis Ag | Novel compound, its use and pharmaceutical composition comprising it |
| DE69612003T2 (de) * | 1995-07-07 | 2001-06-21 | Pfizer | Substituierte benzolaktamverbindungen als substanz-p-antagonisten |
| TW340842B (en) * | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
| US6329396B1 (en) * | 1996-06-10 | 2001-12-11 | Pfizer Inc. | Substituted benzylaminopiperidine compounds |
| ATE234832T1 (de) * | 1999-05-21 | 2003-04-15 | Pfizer Prod Inc | 1-trifluorotmethyl-4-hydroxy-7-piperidinyl- aminomethylchroman-derivate |
| PT1095939E (pt) * | 1999-10-18 | 2004-04-30 | Pfizer Prod Inc | Processo para a preparacao de eteres ciclicos de compostos com piperidinilaminometilo |
-
1998
- 1998-10-21 TW TW087117444A patent/TW426667B/zh not_active IP Right Cessation
- 1998-10-26 CZ CZ20001834A patent/CZ297315B6/cs not_active IP Right Cessation
- 1998-10-26 AU AU94549/98A patent/AU734218B2/en not_active Ceased
- 1998-10-26 DK DK98947726T patent/DK1032571T3/da active
- 1998-10-26 WO PCT/IB1998/001704 patent/WO1999025714A1/en active IP Right Grant
- 1998-10-26 AT AT98947726T patent/ATE219078T1/de not_active IP Right Cessation
- 1998-10-26 TR TR2000/01463T patent/TR200001463T2/xx unknown
- 1998-10-26 EP EP98947726A patent/EP1032571B1/en not_active Expired - Lifetime
- 1998-10-26 UA UA2000042374A patent/UA59417C2/uk unknown
- 1998-10-26 CN CNB988112930A patent/CN1173974C/zh not_active Expired - Fee Related
- 1998-10-26 DE DE69806045T patent/DE69806045T2/de not_active Expired - Fee Related
- 1998-10-26 JP JP2000521096A patent/JP3394239B2/ja not_active Expired - Fee Related
- 1998-10-26 NZ NZ503912A patent/NZ503912A/xx unknown
- 1998-10-26 PT PT98947726T patent/PT1032571E/pt unknown
- 1998-10-26 HU HU0101112A patent/HUP0101112A3/hu unknown
- 1998-10-26 ID IDW20000926A patent/ID24240A/id unknown
- 1998-10-26 RS YUP-294/00A patent/RS49792B/sr unknown
- 1998-10-26 SK SK723-2000A patent/SK283460B6/sk unknown
- 1998-10-26 EA EA200000432A patent/EA002621B1/ru not_active IP Right Cessation
- 1998-10-26 ES ES98947726T patent/ES2177058T3/es not_active Expired - Lifetime
- 1998-10-26 IL IL13563198A patent/IL135631A0/xx not_active IP Right Cessation
- 1998-10-26 CA CA002310627A patent/CA2310627C/en not_active Expired - Fee Related
- 1998-11-11 PA PA19988463001A patent/PA8463001A1/es unknown
- 1998-11-16 PE PE1998001112A patent/PE20000021A1/es not_active Application Discontinuation
- 1998-11-17 MY MYPI98005209A patent/MY120558A/en unknown
- 1998-11-17 MA MA25354A patent/MA26567A1/fr unknown
- 1998-11-17 AR ARP980105829A patent/AR016422A1/es unknown
- 1998-11-18 CO CO98067902A patent/CO4771153A1/es unknown
- 1998-11-18 DZ DZ980265A patent/DZ2655A1/xx active
- 1998-11-18 TN TNTNSN98210A patent/TNSN98210A1/fr unknown
- 1998-11-19 AP APAP/P/1998/001402A patent/AP909A/en active
-
2000
- 2000-04-26 IS IS5470A patent/IS2202B/is unknown
- 2000-05-12 OA OA1200000138A patent/OA11380A/en unknown
- 2000-05-15 BG BG104437A patent/BG63969B1/bg unknown
- 2000-05-17 HR HR960576A patent/HRP20000313B1/xx not_active IP Right Cessation
- 2000-05-18 PL PL98340642A patent/PL193484B1/pl unknown
- 2000-05-18 KR KR10-2000-7005431A patent/KR100366902B1/ko not_active IP Right Cessation
- 2000-05-18 NO NO20002544A patent/NO20002544L/no not_active Application Discontinuation
-
2001
- 2001-06-08 HK HK01103947A patent/HK1033313A1/xx not_active IP Right Cessation
-
2002
- 2002-06-18 JP JP2002177452A patent/JP2003040777A/ja active Pending
-
2003
- 2003-04-21 US US10/419,425 patent/US20030208079A1/en not_active Abandoned
-
2004
- 2004-07-07 NO NO20042879A patent/NO20042879L/no not_active Application Discontinuation
- 2004-11-18 US US10/991,977 patent/US20050171354A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000021A1 (es) | Eteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| PE20040071A1 (es) | Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion | |
| PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
| PE20060627A1 (es) | Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2 | |
| PT1305286E (pt) | Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento | |
| EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
| PE20050465A1 (es) | Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
| AR083483A2 (es) | Proceso para la preparacion del citalopram racemico y del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| DK1778677T3 (da) | Heterocykliske kondenserede forbindelser der er egnede som antidiuretiske midler | |
| AR035502A1 (es) | Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto | |
| AR041302A1 (es) | Compuestos de imidazopiridina como agonistas del receptor 5- ht4 y composiciones farmaceuticas que comprenden dichos compuestos | |
| PE20040120A1 (es) | Derivados de quinolina como antagonistas de npy | |
| PE20011114A1 (es) | Decahidro-isoquinolinas | |
| PE20060557A1 (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas como antagonistas de los receptores trpv1 | |
| PE20030610A1 (es) | Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides | |
| PE20020407A1 (es) | Derivados de quinazolina como antagonistas del receptor adrenergico alfa-1 | |
| JP2004529145A5 (es) | ||
| ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
| PE20030707A1 (es) | Agonistas muscarinicos | |
| PE20060533A1 (es) | Derivados de dicetopiperazina como antagonistas del receptor de oxitocina | |
| MA29336B1 (fr) | Derives d'aryl-1,4-pyrazine substitues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |